{"id":"W3006069344","doi":"10.1097/01.hs9.0000562576.71109.e9","title":"PS1071 PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Vincristine; Prednisone; Internal medicine; CHOP; Cyclophosphamide; Lymphoma; Oncology; Clinical endpoint; CD30; Gastroenterology; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001085837,0.000210307,0.0005287979,0.00005798075,0.00002835976,0.000005684544,0.0001049429,0.00005705549,0.00003197825],"category_scores_gemma":[0.00002652069,0.0001299774,0.00006169781,0.0003170815,0.00005029688,0.0001181818,0.00006414807,0.000089514,0.000007921026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000103612,"about_ca_system_score_gemma":0.00007425038,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000462023,"about_ca_topic_score_gemma":0.0003544185,"domain_scores_codex":[0.9983916,0.0000618296,0.0005677034,0.0003527161,0.0003996639,0.000226431],"domain_scores_gemma":[0.9987867,0.0001034655,0.0003600895,0.0005658663,0.0001359769,0.0000479125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006045617,0.02354089,0.9658571,0.0002788421,0.0000563704,0.00004690458,0.002000339,0.0005063151,0.0006316705,0.000008312545,0.0001442938,0.0008833773],"study_design_scores_gemma":[0.08994706,0.006522081,0.8925536,0.0009753071,0.00009942038,0.000001722235,0.001546615,0.0002371961,0.007904255,0.000003054252,0.00008927611,0.0001203655],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962547,0.0001954478,2.600247e-7,0.0001240952,0.00007518598,0.002577916,0.00005640855,0.00001209669,0.0007039294],"genre_scores_gemma":[0.9994221,0.00002655502,0.00005429857,0.00003106883,0.000008541601,0.00005058451,0.00007349961,0.00002193091,0.000311366],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08390144,"threshold_uncertainty_score":0.5300326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005682963985980265,"score_gpt":0.2428516738576754,"score_spread":0.2371687098716951,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}